NASDAQ : ARVN
Arvinas, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 7.86 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 513.94M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 491.70M |
| Enterprise Value | -68.20M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 65.39M |
| Shares Outstanding | 65.39M |
| Shares Change (YoY) | -7.18% |
| Shares Change (QoQ) | +2.66% |
| Owned by Insiders (%) | 2.48% |
| Owned by Institutions (%) | 76.23% |
| Float | 56.81M |
Ratios
| Measure | Value |
|---|
| PE Ratio | 56.25 |
| Forward PE | n/a |
| PS Ratio | 1.55 |
| Forward PS | 7.12 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 7.91 |
| Quick Ratio | 7.54 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 1.59% |
| Return on Assets (ROA) | -1.01% |
| Return on Invested Capital (ROIC) | -1.35% |
| Return on Capital Employed (ROCE) | -2.16% |
| Weighted Average Cost of Capital (WACC) | 13.94% |
| Revenue Per Employee | $1.29M |
| Profits Per Employee | $37,805 |
| Employee Count | 246 |
| Asset Turnover | 0.40 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 800,000 |
| Effective Tax Rate | 7.92% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.80 |
| 52-Week Price Change | -25.64% |
| 50-Day Moving Average | 8.07 |
| 200-Day Moving Average | 9.66 |
| Relative Strength Index (RSI) | 48.25 |
| Average Volume (20 Days) | 746,189 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.59M |
| Short Previous Month | 5.39M |
| Short % of Shares Out | 8.55% |
| Short % of Float | 9.84% |
| Short Ratio (days to cover) | 6.68 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 316.70M |
| Gross Profit | 307.70M |
| Operating Income | -12.80M |
| Pretax Income | 10.10M |
| Net Income | 9.30M |
| EBITDA | -9.90M |
| EBIT | -12.80M |
| Earnings Per Share (EPS) | $0.13 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 567.90M |
| Total Debt | 8.00M |
| Net Cash | 559.90M |
| Net Cash Per Share | $8.56 |
| Equity (Book Value) | 562.20M |
| Book Value Per Share | 8.61 |
| Working Capital | 569.70M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -207.00M |
| Capital Expenditures | -1.80M |
| Depreciation & Amortization | 2.90M |
| Net Borrowing | -300,000 |
| Free Cash Flow | -208.80M |
| FCF Per Share | -$3.19 |
Margins
| Measure | Value |
|---|
| Gross Margin | 97.16% |
| Operating Margin | -4.04% |
| Pretax Margin | 3.19% |
| Profit Margin | 2.94% |
| EBITDA Margin | -3.13% |
| EBIT Margin | -4.04% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 7.18% |
| Shareholder Yield | 7.18% |
| Earnings Yield | 1.78% |
| FCF Yield | -42.46% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.54 |
| Price Target Difference | 93.35% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | -34.94% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 1.87 |
| Piotroski F-Score | 4 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |